01_02 Latest and greatest in metastatic colon cancer – mAbs, MSI status, sidedness and controversies

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

1. Background on molecular targeted agents

2. VEGF-inhibitors

3. EGFR inhibition

4. Left vs Right sided colon cancer

5. MSI-H/dMMR status

Citations

As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com

DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015.

Uptodate.com Waltham, MA: Wolters Kluwer.

Some highlighted references recommended to read related to this specific episode:

1. Botrel TEA et al. BMC Cancer. 2016;16(1):1-19. doi:10.1186/S12885-016-2734-Y/FIGURES/5

2. Deng T et al. Medical Oncol 2013 30:4. 2013;30(4):1-5. doi:10.1007/S12032-013-0752-Z

3. Hurwitz H et al. NEJM. 2009;350(23):2335-2342. doi:10.1056/NEJMOA032691

4. Booth CM, Goodman AM. Nature Rev Clinl Oncol 2021 18:11. 2021;18(11):673-674. doi:10.1038/s41571-021-00550-9

5. Booth C. J Clin Oncol. 2008;26(28):4693-4694. doi:10.1200/JCO.2008.18.8060

6. Saltz LB et al. J Clin Oncol. 2008;26(12):2013-2019. doi:10.1200/JCO.2007.14.9930

7. Stathopoulos GP et al. Oncology. 2010;78(5-6):376-381. doi:10.1159/000320520

8. Tang W et al. J Clin Oncol. 2020;38(27):3175-3184. doi:10.1200/JCO.20.00174

9. Giantonio BJ et al. J Clin Oncol. 2007;25(12):1539-1544. doi:10.1200/JCO.2006.09.6305

10. van Cutsem E et al. NEJM. 2009;360(14):1408-1417.

11. Cutsem E van, et al. J Clin Oncol. doi:10.1200/JCO.2010.28.15_SUPPL.3570

12. Bokemeyer C et al. Eur J Cancer. 2012;48(10):1466-1475. doi:10.1016/J.EJCA.2012.02.057

13. Tejpar S et al. JAMA Oncol. 2017;3(2):194-201. doi:10.1001/JAMAONCOL.2016.3797

14. Venook AP et al. JAMA. 2017;317(23):2392-2401. doi:10.1001/JAMA.2017.7105

15. Maughan TS et al. The Lancet. 2011;377(9783):2103-2114

16. Lenz HJ et al. J Clin Oncol. 2019;37(22):1876-1885. doi:10.1200/JCO.18.02258

17. Venook A et al. Ann Oncology. 2014;25(2):ii112. doi:10.1093/ANNONC/MDU193.19

18. Shiu KK et al. J Clin Oncol https://doi.org/101200/JCO2021393_suppl6. 2021;39(3_suppl):6-6. doi:10.1200/JCO.2021.39.3_SUPPL.6

19. André T et al. NEJM 2020;383(23):2207-2218.

20. Jonker DJ al. NEJM. 2009;2(11):2040-2048. doi:10.1056/NEJMOA071834

21. Brulé SY et al. Eur J Cancer. 2015;51(11):1405-1414. doi:10.1016/J.EJCA.2015.03.015

22. Tol J et al. NEJM. 2009;360(6):563-572.

Disclosures

Talking about Tumors with Ryan and Ryann is not medical advice. We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose. All opinions are those of whoever stated them. We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.